Your browser doesn't support javascript.
loading
Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.
Ciron, Jonathan; Cobo-Calvo, Alvaro; Audoin, Bertrand; Bourre, Bertrand; Brassat, David; Cohen, Mikael; Collongues, Nicolas; Deschamps, Romain; Durand-Dubief, Françoise; Laplaud, David; Maillart, Elisabeth; Papeix, Caroline; Zephir, Hélène; Bereau, Matthieu; Brochet, Bruno; Carra-Dallière, Clarisse; Derache, Nathalie; Gagou-Scherer, Clarisse; Henry, Carole; Kerschen, Philippe; Mathey, Guillaume; Maubeuge, Nicolas; Maurousset, Aude; Montcuquet, Alexis; Moreau, Thibault; Prat, Christophe; Taithe, Frédéric; Thouvenot, Eric; Tourbah, Ayman; Rollot, Fabien; Vukusic, Sandra; Marignier, Romain.
Afiliação
  • Ciron J; Department of Neurology, Centre de Ressources et Compétences Sclérose en Plaques, Toulouse University Hospital, Toulouse, France.
  • Cobo-Calvo A; Pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Lyon, France; Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle and INSERM U1028, CNRS UMR 5292, Lyon 1 University, Center for Research in Neuroscience of L
  • Audoin B; Department of Neurology, Hôpital de La Timone, APHM, Marseille, France; Aix-Marseille University, Marseille, France.
  • Bourre B; Department of Neurology, Rouen University Hospital, Rouen, France.
  • Brassat D; Department of Neurology, Centre de Ressources et Compétences Sclérose en Plaques, Toulouse University Hospital, Toulouse, France.
  • Cohen M; Centre de Ressources et Compétences SEP, Neurologie, Université Nice Côte d'Azur, CHU Pasteur 2, Nice, France.
  • Collongues N; Department of Neurology, Strasbourg University Hospital, Strasbourg, France.
  • Deschamps R; Department of Neurology, Fondation A. De Rothschild, Paris, France.
  • Durand-Dubief F; Department of Neurology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.
  • Laplaud D; Department of Neurology, Nantes University Hospital, Nantes, France.
  • Maillart E; Department of Neurology, Pitié-Salpêtrière Hospital, APHP, Paris, France.
  • Papeix C; Department of Neurology, Pitié-Salpêtrière Hospital, APHP, Paris, France.
  • Zephir H; Department of Neurology, Lille University Hospital, Lille, France; LIRIC UMR 995, Lille, France.
  • Bereau M; Department of Neurology, Besançon University Hospital, Besançon, France.
  • Brochet B; Department of Neurology, Bordeaux University Hospital, Bordeaux, France.
  • Carra-Dallière C; Department of Neurology, Montpellier University Hospital, Montpellier, France.
  • Derache N; Department of Neurology, Caen University Hospital, Caen, France.
  • Gagou-Scherer C; Department of Neurology, Angers University Hospital, Angers, France.
  • Henry C; Department of Neurology, Paris Saint-Denis Hospital, Paris, France.
  • Kerschen P; Department of Neurology, Centre Hospitalier Luxembourg, Luxembourg.
  • Mathey G; Department of Neurology, Nancy University Hospital, Nancy, France.
  • Maubeuge N; Department of Neurology, Poitiers University Hospital, Poitiers, France.
  • Maurousset A; Department of Neurology, Tours University Hospital, Tours, France.
  • Montcuquet A; Department of Neurology, Limoges University Hospital, Limoges, France.
  • Moreau T; Department of Neurology, Dijon University Hospital, Dijon, France.
  • Prat C; Department of Neurology, Angoulême Hospital, Angoulême, France.
  • Taithe F; Department of Neurology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
  • Thouvenot E; Department of Neurology, Nîmes University Hospital, Nîmes, France.
  • Tourbah A; CHU de Reims and Université Reims Champagne Ardenne, LPN, EA 2027 Université Paris 8, Saint-Denis, France.
  • Rollot F; Claude Bernard Lyon 1 University, Villeurbanne, France.
  • Vukusic S; Pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Bron, France; Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle and INSERM U1028, CNRS UMR 5292, Lyon 1 University, Center for Research in Neuroscience of L
  • Marignier R; Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Hôpital Neurologique Pierre Wertheimer Hospices Civils de Lyon, Bron, France; Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle and INSERM U1028, CNRS UMR 5292, Lyon 1 Universi
Mult Scler ; 26(8): 936-944, 2020 07.
Article em En | MEDLINE | ID: mdl-31148523
ABSTRACT

OBJECTIVES:

We aim to (1) determine the frequency and distinctive features of short myelitis (SM) and longitudinally extensive transverse myelitis (LETM) in a cohort of adults with myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated myelitis and (2) determine baseline prognostic factors among MOG-Ab-positive patients whose disease started with myelitis. MATERIAL AND

METHODS:

We retrospectively analyzed clinical and paraclinical variables from a multicentric French cohort of adults with MOG-Ab-associated myelitis. At last follow-up, patients were classified into two groups according to the severity of the Expanded Disability Status Scale (EDSS) as ⩽2.5 or ⩾3.0.

RESULTS:

Seventy-three patients with at least one episode of myelitis over disease course were included; among them, 28 (38.4%) presented with SM at the time of the first myelitis. Motor and sphincter involvement was less frequently observed in SM (51.9% and 48.2%, respectively) than in LETM patients (83.3% and 78.6%, respectively), p = 0.007 and p = 0.017; 61% of LETM patients displayed brain lesions compared to 28.6% in the SM group, p = 0.008, and the thoracic segment was more frequently involved in the LETM (82.2%) than in the SM group (39.3%), p < 0.001. EDSS at last follow-up was higher in LETM (median 3.0 (interquartile range 2.0-4.0)) compared to SM patients (2.0, (1.0-3.0)), p = 0.042. Finally, a higher EDSS at onset was identified as the only independent risk factor for EDSS ⩾3.0 (odds ratio, 1.40, 95% confidence interval (CI) 1.01-1.95, p = 0.046).

CONCLUSION:

SM in MOG-Ab-associated disease is not rare. The severity at onset was the only independent factor related to the final prognosis in MOG-Ab-associated myelitis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Autoanticorpos / Índice de Gravidade de Doença / Sistema de Registros / Progressão da Doença / Glicoproteína Mielina-Oligodendrócito / Mielite Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mult Scler Assunto da revista: NEUROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Autoanticorpos / Índice de Gravidade de Doença / Sistema de Registros / Progressão da Doença / Glicoproteína Mielina-Oligodendrócito / Mielite Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mult Scler Assunto da revista: NEUROLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: França